跳至主要内容
临床试验/NCT01833793
NCT01833793已完成不适用

Mirena and Amenorrhea Related acceptabILity in Contraception indIcAtion

Bayer0 个研究点目标入组 35 人开始时间: 2013年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
35
主要终点
Proportion of Mirena users who have at least one period of Amenorrhea of at least three months

研究概览

简要总结

MARILIA is a prospective, non-interventional, multicenter study. The purpose of this study is to describe the acceptability of Amenorrhea in contraception indication of Mirena users during one year follow up in medical practice. 500 patients in 20 centers will be enrolled in the study. Bleeding profile, removal or non-removal of the IUS (IntraUterine System) will be evaluated.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Age 19-40 years at the time of Mirena IUD insertion
  • Using Mirena only for contraception indication
  • Never having used the product before
  • No heavy menstrual bleeding diagnosed
  • Have signed informed consent to participate in this study

排除标准

  • Nulliparous
  • Pregnancy
  • Mirena's contre-indication
  • Mirena for HMB
  • Abnormal bleeding pattern

研究组 & 干预措施

Group 1

干预措施: Levonorgestrel IUD (Mirena, BAY86-5028) (Drug)

结局指标

主要结局

Proportion of Mirena users who have at least one period of Amenorrhea of at least three months

时间窗: 12 months

Cumulative incidence rate of Amenorrhea over the duration of follow up period in Mirena users

时间窗: 12 months

次要结局

  • Proportion of Mirena users with menorrhagia(12 months)
  • Cumulative rate of satisfaction in Mirena users(12 months)
  • Proportion of Mirena users who have menstrual disorders(12 months)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验